MAPK7 and glioblastoma: These results were further validated using the HPA and GlioVis database analyses, which showed similar outputs displaying overexpression of CCNB1/CDC42/MAPK7/CD44 gene signatures in WHO grade II, III, and IV GBM tumors using an ANOVA.